Mentice

Mentice EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Mentice (MNTC.ST) as of Nov 19, 2026 is -10.89. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -29.04 — a change of -62.50% (higher).

EV/EBIT

-10.89

YoY

-62.50%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Mentice is 2025 -10.89 . EV/EBIT (Enterprise Value to EBIT) of Mentice was 2024 -29.04 . It decreases by -62.50% higher compared to the previous year.

The Mentice EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-12.95 SEK
Jan 1, 2020
-11.40 SEK
Jan 1, 2021
-17.36 SEK
Jan 1, 2022
-15.88 SEK
Jan 1, 2023
-530.21 SEK
Jan 1, 2024
-29.04 SEK
Jan 1, 2025
-10.89 SEK
Jan 1, 2026 (e)
-59.54 SEK
The Mentice EV/EBIT history
YEAREV/EBITYoY
est-59.54+446.76%
-10.89-62.50%
-29.04-94.52%
-530.21+3,238.29%
-15.88-8.52%
-17.36+52.34%
-11.40-11.97%
-12.95-158.00%
22.32-59.44%
55.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Mentice's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Mentice's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Mentice's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Mentice grows earnings faster than its peers.

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

EV/EBIT (Enterprise Value to EBIT) of Mentice is -10.89 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Mentice changed from -29.04 to -10.89, representing a -62.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Mentice since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Mentice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Mentice

All Key Metrics — Mentice